Beatriz Martín-Antonio

Instituto de Salud Carlos III — Spain

Medicine · Health Sciences

27h-index2.5kcitations222works0.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(92), Multiple Myeloma Research and Treatments(87), Protein Degradation and Inhibitors(50), Immune Cell Function and Interaction(41), Biosimilars and Bioanalytical Methods(32)

Publications222 total

Lentiviral-mediated panErbB CAR-T cell therapy against head and neck squamous cell carcinomas for patients with Fanconi anemia
Molecular Therapy Oncology·2025Open Access
Adoptive transfer of NK cells engineered with a CD5-based chimeric antigen receptor (SRCD5CAR) to treat invasive fungal infections
Molecular Therapy·2025· 1 citedOpen Access
Supplementary Figure 18 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
2025Open Access
Supplementary Figure 4 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
2025Open Access
Supplementary Figure 16 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
2025Open Access
Supplementary Table 11 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
2025Open Access
Supplementary Figure 3 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
2025Open Access
Supplementary Table 16 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
2025Open Access
Supplementary Figure 1 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
2025Open Access
Supplementary Table 9 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
2025Open Access
Supplementary Table 8 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
2025Open Access
Supplementary Table 17 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
2025Open Access
Supplementary Figure 12 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
2025Open Access
Supplementary Figure 8 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
2025Open Access
Supplementary Table 13 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
2025Open Access
Supplementary Figure 6 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
2025Open Access
Supplementary Table 6 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
2025Open Access
Supplementary Figure 21 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
2025Open Access
Supplementary Figure 20 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
2025Open Access
Supplementary Table 10 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
2025Open Access
page 1 of 12Next →

Frequent Co-authors

Álvaro Urbano-Ispizúa(26), Carlos Fernández de Larrea(14), Manel Juan(13), Lorena Pérez-Amill(10), Laura Rosiñol(10), Aina Oliver‐Caldés(8), Luis Gerardo Rodríguez‐Lobato(8), Guillermo Suñé(7), Marta Español‐Rego(7), Mariona Pascal(7), Manuel Manchado(6), María Castellà(6), Clara Bueno(6), Susana Inogés(6), Natalia Tovar(6), María Teresa Cibeira(6), Joan Bladé(6), Valentín Ortiz‐Maldonado(5), Julio Delgado(5), Paula Rodríguez‐Otero(5)